J Clin Psychopharmacol. 2025 Sep 3. doi: 10.1097/JCP.0000000000002061. Online ahead of print.
ABSTRACT
PURPOSE/BACKGROUND: Multiple meta-analyses have suggested that pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. However, these meta-analyses included studies with different PGx tests and different trial designs, which produce uncertainty when interpreting results. To investigate the clinical utility of a single weighted multigene PGx test, a meta-analysis was performed for prospective studies utilizing this PGx test in adult patients with MDD.
METHODS/PROCEDURES: MEDLINE/PubMed and Cochrane [including Embase, clinicaltrials.gov, and International Clinical Trials Registry Platform (ICTRP)] were searched through May 2025 for studies evaluating the impact of pharmacogenomic testing on outcomes for patients with MDD. Using PRISMA guidelines, 243 records were identified, and 6 studies were included that compared PGx-guided care to unguided care in adult patients with MDD, using a single weighted multigene test.
FINDINGS/RESULTS: Overall, 3,532 patients were included, with outcomes evaluated at week 8 or week 10. Patients with MDD whose care was guided by the weighted multigene PGx test were 30% more likely to achieve response [relative risk ratio (RR)=1.30, 95% CI: 1.16-1.47, P<0.001] and 41% more likely to achieve remission [RR=1.41, 95% CI: 1.19-1.66, P<0.001] compared to unguided care. No heterogeneity in outcomes across studies was detected.
IMPLICATIONS/CONCLUSIONS: Prescribing informed by a weighted multigene PGx test significantly improved response and remission rates among adult patients with MDD who experienced at least 1 prior treatment failure, further demonstrating the clinical utility of weighted multigene PGx testing.
PMID:40901805 | DOI:10.1097/JCP.0000000000002061
Recent Comments